使用患者的偏好来告知ritlecitinib的剂量选择,以治疗脱发症
Brett Hauber1, Chiara Whichello2, Jonathan Mauer1
1Pfizer Inc., New York, New York, USA.
The Journal of dermatology
|January 15, 2025
概括
患有严重脱发症 (AA) 的患者接受Ritlecitinib增加头发再生的风险更高. 与30毫克剂量相比,50毫克剂量提供了更大的疗效,患者更重视严重感染,癌症或血栓风险的潜在增加,而不是30毫克剂量.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 皮肤病学 皮肤病学
- 患者报告的结果
背景情况:
- 利特利西丁是口服的Janus激酶3/氨酸激酶,表达在肝细胞癌 (JAK3/TEC) 家庭激酶抑制剂中,已被批准用于严重脱发区 (AA).
- 了解患者对益处风险概况的偏好对于优化AA治疗决策至关重要.
研究的目的:
- 为了评估两剂Ritelecitinib (50毫克对30毫克每天一次) 治疗严重脱发症 (AA) 的益处风险概况.
- 量化患者接受风险的意愿,以提高AA治疗的疗效.
主要方法:
- 一个离散选择实验 (DCE) 用于引起患者对系统AA治疗相关的益处 (头皮,眉毛,毛毛发再生) 和风险 (严重感染,癌症,血栓) 的偏好.
- 计算了最大可接受风险 (MAR) 预期的益处增加,当选择较高的利特列西提尼布剂量 (50 mg) 而不是较低的剂量 (30 mg) 时.
- 从201名患有严重AA (头皮脱发≥50%) 的成年人中收集了数据.
主要成果:
- 患者会接受严重感染 (平均3.88%),癌症 (1.63%) 和血栓 (5.30%) 的3年风险增加,以增加头皮,眉毛和毛毛重生的概率.
- 计算的MAR表明患者更喜欢更高的疗效,即使伴有更高的风险.
- 这些发现将患者的偏好与ritlecitinib的临床疗效和安全性数据相结合.
结论:
- 成年患者患有严重的AA值头发再生,并且愿意接受增加的风险,以获得50毫克里特利西提尼比30毫克剂量更高的疗效.
- DCE方法有效地测量风险耐受性,并可以为AA治疗提供最佳剂量选择的信息.
- 里特利西提尼布的益处风险概况对于优先考虑显著头发再生的患者来说是有利的.
相关概念视频
Renal Failure: Dose Adjustments
62
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tissue-Drug Binding: Localization of Drugs and its Significance
61
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
61
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
134
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
134
Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.8K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.8K


